Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2013-07-11 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse nr. 16/2013" (Company Announcement No. 16/2013) and is dated July 11, 2013. It announces positive results from a Phase III clinical trial (MITRA study) for a new tablet vaccine against house dust mite-induced asthma. It discusses clinical data, regulatory plans (European approval submission in 2014), and future data presentation schedules (in the Q2 interim report). This type of announcement, which is a formal, time-sensitive communication about significant business/clinical developments, fits best under the general category for regulatory announcements that are not specific financial reports (like 10-K or ER) or management changes. Since it is a formal company announcement that doesn't fit the highly specific categories like DIV, DIRS, or DEF 14A, the most appropriate classification is the general regulatory filing fallback category, RNS (Regulatory Filings). The document length is substantial (6397 chars), but its nature is that of a press release/announcement, not a full statutory report.
2013-07-11 English
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a press release dated June 19, 2013, announcing positive top-line results from a Phase III clinical trial (MERIT) for an allergy immunotherapy tablet. It details the trial's primary endpoint achievement, safety profile, and implications for future regulatory filings (European filing in 2014). It also mentions ongoing trials (MITRA) and partnerships. This content is a specific announcement of clinical trial results and development progress, which is not explicitly covered by the core financial filings (10-K, IR, ER, MRQ). Since it is an announcement about clinical development and regulatory pathway updates, and not a formal financial report, dividend notice, or management change, it best fits the general 'Regulatory Filings' category (RNS) as a significant corporate update that doesn't fit the other specific categories, or potentially a general Investor Relations document. Given the focus on trial outcomes and regulatory next steps, RNS (Regulatory Filings) is the most appropriate fallback for a non-standard, material corporate announcement.
2013-06-19 English
Earnings Release 2013
Earnings Release Classification · 95% confidence The document is a press release dated June 19, 2013, announcing positive top-line results from a Phase III clinical trial (MERIT study) for a new tablet vaccine against house dust mite allergy. It details the study's primary endpoint achievement, safety profile, and implications for future regulatory submissions (European approval in 2014). It also mentions ongoing studies (MITRA) and partnerships (Torii, Merck). This content is characteristic of an initial announcement of key financial/clinical performance data, rather than a comprehensive report (10-K or IR) or a transcript (CT). It fits best under 'Earnings Release' (ER) as it announces key performance/development results, even though it's clinical data rather than pure financial earnings, or potentially 'Regulatory Filings' (RNS) if it were a general update. Given the focus on announcing positive results that impact future regulatory strategy, ER is the most appropriate fit among the specific options, as it functions as a major operational/development update release. Q2 2013
2013-06-19 Danish
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a press release dated May 8, 2013, announcing that the FDA has accepted the registration application for ragweed AIT (allergen immunotherapy) from ALK's North American partner, Merck. It discusses regulatory progress, clinical trial results, and partnership details. This type of announcement, detailing progress in regulatory submissions or clinical trials that is not a full financial report (like 10-K or IR) or a specific insider trade/dividend notice, falls best under the general category of Regulatory Filings (RNS) or potentially a Legal/Regulatory update, but RNS is the most appropriate general regulatory announcement category when specific codes like LTR or CAP do not apply. Since it is an announcement about a regulatory step (FDA acceptance), RNS is the best fit as a general regulatory communication.
2013-05-08 Danish
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a press release dated May 8, 2013, announcing that the FDA has accepted the Biologics License Application (BLA) for an allergy immunotherapy tablet (AIT) from ALK's partner, Merck. This announcement concerns regulatory progress and partnership activities related to product registration, rather than being a full financial report (10-K, IR), an earnings release (ER), or a formal shareholder vote result (DVA). Since it details a specific regulatory step (FDA acceptance of BLA) and is a general corporate announcement, it fits best under the 'Regulatory Filings' (RNS) category as a general regulatory update that doesn't fit the more specific categories like M&A (TAR) or Director's Dealing (DIRS). Given the short length and nature as an announcement, RNS is the most appropriate fallback.
2013-05-08 English
Report Publication Announcement 2013
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1675 chars) in Danish. It explicitly states that ALK will publish its interim report for Q1 2013 on May 3rd, 2013, and subsequently hold an information meeting (investor/analyst call) where results and expectations will be presented. The text focuses on announcing the timing of the report release and the associated conference call/presentation, rather than containing the full financial report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement about the publication of a report points towards a Report Publication Announcement (RPA).
2013-04-30 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.